SCHEMBL22769065

SCHEMBL22769065

CNCCCC[C@H](N)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.43
GNAI3 P08754 1/20 0.41
GNAO1 P09471 1/20 0.41
GNAI1 P63096 1/20 0.41
KISS1R Q969F8 1/20 0.39
NOS2 P35228 6/20 0.38
NOS1 P29475 4/20 0.38
NOS3 P29474 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
GSR P00390 1/20 0.38
BLM P54132 1/20 0.37
CPB2 Q96IY4 1/20 0.36
DDAH1 O94760 1/20 0.36
RRM1 P23921 1/20 0.36
MEN1 O00255 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC15A1 P46059 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13456304 1.00 DPP7 (0.43) DPP7GNAI3GNAO1GNAI1KISS1R
SCHEMBL20653680 1.00 DPP7 (0.43) DPP7GNAI3GNAO1GNAI1KISS1R
SCHEMBL16421611 0.94 KISS1R (0.44) DPP7GNAI3GNAO1GNAI1KISS1R
SCHEMBL12779148 0.94 KISS1R (0.44) DPP7GNAI3GNAO1GNAI1KISS1R
Hydrochloric Acid SCHEMBL28656624 0.92 KISS1R (0.43) DPP7GNAI3GNAO1GNAI1KISS1R
Hydrochloric Acid SCHEMBL28656623 0.92 KISS1R (0.43) DPP7GNAI3GNAO1GNAI1KISS1R
SCHEMBL14288769 0.85
SCHEMBL432790 0.83 GSR (0.57) NOS2NOS1NOS3CYP1A2CYP3A4
SCHEMBL64149 0.83 GSR (0.57) NOS2NOS1NOS3CYP1A2CYP3A4
SCHEMBL12825453 0.83 KISS1R (0.47) DPP7GNAI3GNAO1GNAI1KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023233042-A1 POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY BIO-TRIP B.V. (NL) 2023-12-07 WO disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 US disclosed
US-20220273807-A1 CONJUGATES FOR USE IN METHODS OF TREATING CANCER ASTRAZENECA AB (SE) 2022-09-01 US disclosed
WO-2020247297-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220273807-A1 CONJUGATES FOR USE IN METHODS OF TREATING CANCER CD44, FOLH1, SLC17A5 DPP7 1481/4885GNAI3 2268/4885GNAO1 2556/4885
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP DPP7 3248/4885GNAI3 3702/4885GNAO1 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.